INN-Coming: Insights on the Industry’s Latest Disclosures
The WHO’s INN proposed list 134, released in early 2026, reveals several late‑stage drug candidates that were previously hidden from public view. Notably, two NLRP3 inhibitors—abdenoflast and parunoflast—appear to map to Eli Lilly’s newly acquired Ventyx assets VTX2735 and VTX3232, both showing promising Phase 2 data. The list also discloses LRRK2 inhibitors liradasertib and pelerasertib, which likely correspond to Denali Therapeutics’ DNL151 (BIIB122) and Halia Therapeutics’ HT‑4253, indicating continued investment in neuro‑degenerative targets. These disclosures provide a rare glimpse into the strategic pipelines of major biotech players.
Module 2, Section 2: The Druggable Interactome
The Module 2, Section 2 lecture introduces the druggable interactome, compiling key resources that map the human druggable genome, protein expression, kinase families, transcription‑factor proteomics, GPCRs, and ion‑channel complexes. It highlights quantitative estimates—over 3,000 proteins deemed druggable and hundreds of actionable kinases—while...
Best Practices for Applying HDX-MS to FBLD
A recent open‑access study demonstrates that hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) can reliably map binding sites of extremely weak fragment hits (up to 7 mM KD) against Cyclophilin D. By optimizing protein concentration at 10 µM and testing fragments at 2.5‑10 mM, the...
Real-World Data Brings New Insights to Natural History of Disease Studies
Real‑world data (RWD) is reshaping natural history studies by delivering longitudinal, patient‑level information that was previously only obtainable through costly prospective trials. Advances in artificial intelligence and natural language processing now allow rapid extraction of structured data from unstructured sources...
What’s Your Cold Chain Testing Telling You?
Altor is hosting a free webinar on March 12, 2026 to teach cold‑chain professionals best practices in thermal testing. The session will cover how nuanced variables affect test outcomes and which questions to ask to validate designs. Speakers include Altor’s Director of...
Fresh Formats, a Debut Event Director, and a New Viennese Venue for LogiPharma 2026
LogiPharma 2026 will debut in Vienna’s Austria Center, moving from France after four years. Under new event director Ben Sharples, the conference introduces interactive panels, Oxford‑style debates and hands‑on training through the LogiPharma Academy. The program splits into two interconnected...
Weekly Reads: Longevity Hype Vs. Cool Research, Losing Your Y, FDA Maelstrom
This week’s coverage juxtaposes longevity hype with emerging science, highlighting David Sinclair’s bold claim that aging could be reversed within 10‑20 years, a new Nature paper confirming adult hippocampal neurogenesis, and research showing men lose the Y chromosome as they...
Epic's First Pharma Deal
Epic Systems announced its first pharmaceutical customer, Eli Lilly, for the newly launched Epic Discovery platform. The deal marks the inaugural sale of a Health Grid product to a life‑sciences firm, allowing Lilly to streamline clinical trial creation, site identification, activation,...
Cybersecurity and AI in the Era of Home-Based Care Logistics
Kenco’s vice‑president of life sciences, Tim McClatchy, detailed how the firm is hardening cybersecurity across its manufacturer‑to‑home delivery network while deploying AI to streamline labor planning and route optimization. He explained the specific encryption and verification steps used at each...
Pharmaceutical Executive Daily: FDA Approves Hernexeos
The FDA approved Hernexeos through the national priority voucher program, a mechanism that fast‑tracks drugs addressing unmet medical needs. Industry leaders are evaluating direct‑to‑consumer (DTC) models to broaden access to HIV prevention tools, leveraging digital and telehealth channels. Additionally, the...
A Tale of Three Bispecific Cities
Three bispecific antibodies targeting PD‑1 and CTLA‑4—lorigerlimab, volrustomig, and cadonilimab—illustrate divergent engineering strategies. Lorig erlimab relies on a knob‑into‑hole heterodimer, volrustomig adopts a common light chain format, and cadonilimab incorporates Fc‑silencing mutations. Their distinct designs have produced markedly different safety...
Cellular Reprogramming: The Expert Roundup
A round‑up of leading experts highlights how cellular reprogramming has moved from a laboratory curiosity to a near‑clinical anti‑aging platform. Researchers describe partial, epigenetic‑focused approaches that can rejuvenate cells without erasing identity, and four biotech firms outline their distinct delivery...
FAQ: Inflation Reduction Act and Medicare Drug Pricing
The Inflation Reduction Act reshapes Medicare Part D by granting CMS authority to negotiate prices for high‑cost drugs and instituting a $2,100 annual out‑of‑pocket cap for beneficiaries starting this year. The first ten drugs, including Ozempic and Wegovy, will have negotiated...
Pharma M&A in 2026: Can the Industry Keep Up the Momentum?
Dan Chancellor of Norstella explains that the looming patent cliff and persistent growth gaps are forcing pharma companies to rely heavily on mergers and acquisitions. 2025 saw a record $220 billion in deal value, driven by several mega‑transactions and numerous bolt‑on...
Transduction-Ready Viral Particles
AMSBIO (Oxford, UK) now provides ready‑to‑use lentiviral particles with titers exceeding 1×10⁷ IFU / mL, eliminating the need for in‑house virus production. The third‑generation self‑inactivating vectors are supplied in research‑grade and GMP‑grade formats, requiring only BSL‑2 containment. High‑titer, purified particles enable efficient...
Polyploidy and Cellular Senescence Are Tangled Together
Researchers highlight that senescent cells arising from DNA replication errors that generate whole‑chromosome duplications—polyploidy‑induced senescence (PIS)—are biochemically distinct from senescence caused by other stresses. Existing literature often fails to separate polyploid senescent cells from diploid counterparts, obscuring their unique roles...
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
Gilead’s U.S. HIV prevention VP Ashley Gildea unveiled a direct‑to‑consumer campaign for Yeztugo, the first twice‑yearly injectable PrEP. The campaign, anchored by a music‑driven “One2PrEP” spot, aims to lift awareness among the estimated 2.2 million Americans who could benefit from PrEP...
Pharma Pulse: The Oral GLP-1 Battle and GSK’s Billion-Dollar Breath of Fresh Air
Eli Lilly’s oral GLP‑1 small‑molecule orforglipron demonstrated greater A1C reduction and weight loss than oral semaglutide, while offering flexible dosing without fasting. GSK announced a $950 million acquisition of 35Pharma, securing HS235, an activin‑signaling inhibitor aimed at pulmonary hypertension. The deal taps...
AI Designs Better Drug Candidates with Quantum Aid
Researchers from Japan Tobacco and D‑Wave have unveiled a hybrid framework that merges deep generative models with quantum annealing to design drug‑like molecules. The system introduces a Neural Hash Function that enables binarisation for quantum processing while preserving gradient flow....
January 2026 Patent Highlights
The January 2026 Patent Highlights roundup spotlights a wave of new intellectual‑property activity across several cutting‑edge drug discovery areas. Notable filings include lysine‑directed covalent inhibitor chemotypes, strategies to balance potency with drug‑like properties, refined target‑selection frameworks, dozens of Polθ synthetic‑lethal patents...
Most Detailed Spatial Atlas yet for Mapping the Pancreatic Tumor Microenvironment
An international team led by the University of Birmingham, University Hospitals Birmingham NHS Foundation Trust and Bristol Myers Squibb has produced the most detailed spatial atlas of pancreatic ductal adenocarcinoma (PDAC) to date. Using spatial transcriptomics and spatial molecular imaging...
Covalent Organic Frameworks Assembled Inside Tumor Cells Trigger Cancer Cell Death and Immune Activation
Researchers at the University of Macau have demonstrated the first in‑situ synthesis of covalent organic frameworks (COFs) inside lysosomes of cancer cells, using acidic pH‑driven imine condensation of TAPB and DMTP. The crystalline UMCOF1 particles rupture lysosomal membranes, liberating ferrous...
Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO
Sarepta Therapeutics announced that CEO Douglas Ingram will retire by the end of 2026, triggering a formal succession search. The move follows a turbulent 2025 in which the company’s flagship gene therapy Elevidys was linked to two patient deaths, prompting...
How Takeda Is Harnessing RWE, Patient Insights and Human-Focused AI to Advance Global Access
Takeda is leveraging real‑world evidence (RWE) and human‑focused AI to reshape clinical trial design, patient access, and global market strategies. Chief Medical Officer Awny Farajallah highlights three pillars: robust evidence generation, capability building, and early patient access. RWE is used...
What Does the Rollout of Trump Rx Reveal?
Buzz Health President Joseph Kleiman says TrumpRx is advancing drug‑price transparency by giving consumers early visibility into prescription costs. He notes that real‑time pricing can help patients compare options but also warns that prices are dynamic and may change before...
Leading in the Psychedelic Space: Q&A with Tarek Rabah
Otsuka America became the first major pharmaceutical company to back psychedelic‑inspired medicines in 2020 through a partnership with COMPASS Pathways, and deepened that commitment by acquiring Mindset in 2023. The company is applying its long‑standing CNS expertise to develop serotonergic...
Women’s HealthX Launches in Boston This December to Transform Women’s Health Through Data and Science
Women’s HealthX (WoHX) will convene 750 pharma, biotech, hospital, insurer, startup and government leaders in Boston on December 3‑4, 2026. The two‑day summit aims to close the sex‑difference data gap by showcasing evidence‑based technologies, AI tools and digital therapeutics across the...
Surprise! Fifth Circuit Rejects DEA’s Longstanding Interpretation of a Pharmacist’s “Corresponding Responsibility” And “Usual Course of Professional Practice” Regulations
The Fifth Circuit rejected the DEA’s long‑standing reading of the pharmacist’s “corresponding responsibility” and “usual course of professional practice” regulations, ruling that liability requires proof a prescription was invalid when issued and that the pharmacist actually knew it was invalid....
Leading Women CEOs Across Pharma and Biotech: A 2026 Snapshot
2026’s leading women CEOs in pharma and biotech are steering some of the industry’s biggest strategic moves, from multi‑billion‑dollar investments to landmark FDA approvals. The list includes Julie Kim’s upcoming Takeda leadership, Emma Walmsley’s transition at GSK, Reshma Kewalramani’s growth...
Dotinurad (FYU-981)
Dotinurad (FYU‑981), marketed as Urece®, is a URAT1 inhibitor approved for gout and hyperuricemia in Japan and China. The drug was chemically refined from the older uricosuric benzbromarone to retain potency while eliminating rare hepatotoxic events. Crystalys Therapeutics is now...
Rare Disease Day Insight: Epilepsy Care Gaps in Pregnancy with UCB’s Andrea Wilkinson — Episode 244
The Xtalks Life Science Podcast’s Episode 244 spotlights a persistent gap in epilepsy care for pregnant women, noting that fewer than 5% of clinical trials include this population. Andrea Wilkinson, UCB’s Global Head of Patient Engagement & Advocacy, discusses new...
Pharmaceutical Executive Daily: FDA Approves Braftovi
The FDA has approved Braftovi for patients with BRAF V600E‑mutant metastatic colorectal cancer, expanding targeted options in a genetically defined subset. The clearance underscores the momentum of biomarker‑driven oncology and combination‑therapy strategies. In parallel, Novo Nordisk announced a $2 billion partnership with Vivtex...
Menopausal Hormone Therapy Does Not Increase Mortality
A Danish register study of over 800,000 women examined the long‑term safety of menopausal hormone therapy (MHT). About 12% of participants used MHT for a median of 1.7 years, and the analysis found no association between MHT use and all‑cause...
Medicines and Healthcare Products Regulatory Agency Confiscates 2,000 Doses of Illegal Weight-Loss Drugs: Report
Britain's Medicines and Healthcare products Regulatory Agency (MHRA) seized nearly 2,000 doses of illegal weight‑loss drugs in raids on sites in Lincolnshire and Nottinghamshire, marking its second major operation in four months. The confiscated products were labelled as containing tirzepatide...
Emerging Key Trends in Hematologic Malignancies
The article argues that the next wave of hematologic‑malignancy therapies will be shaped by early‑stage signals emerging from conference hallways rather than headline‑grabbing late‑phase trial data. It identifies five nascent trends—advanced immunotherapies, precision genomics, micro‑environment targeting, novel biomarker platforms, and...
Generate Biomedicines (GENB) IPO Deck
Generate Biomedicines (GENB) filed its IPO prospectus, unveiling a programmable biology platform that engineers therapeutic proteins previously considered undruggable. The company highlighted a pipeline featuring oncology and immunology candidates that have progressed to Phase 2 trials, supported by early efficacy signals....
Tooth Whitening without Enamel Damage? Vibration-Activated Powder Protects Pearly Whites for Better Oral Health
Researchers at Shanghai Xuhui District Stomatological Hospital and the Chinese Academy of Sciences have engineered a vibration‑activated teeth‑whitening powder (BSCT) that works with electric toothbrushes. The ceramic powder uses piezoelectric catalysis to generate reactive oxygen species for stain removal while...
FDA Enforcement on Copycat GLP-1's Could Reshape Retail Pharmacy Economics: Q&A with David Graziano
The FDA’s crackdown on non‑approved or “copycat” GLP‑1 drugs is expected to push patients toward FDA‑approved therapies, elevating the role of retail pharmacies as primary access points. GoodRx’s head of retail network, David Graziano, says the company’s cost‑plus pricing model...
Filkri Becomes Fifth FDA-Approved Neupogen Biosimilar
Accord BioPharma’s Filkri (filgrastim‑laha) received FDA approval as the fifth biosimilar to Amgen’s Neupogen. The indication set mirrors Neupogen’s, covering chemotherapy‑induced neutropenia, AML, bone‑marrow transplant, severe chronic neutropenia, and radiation‑induced syndrome. Approval was based on two randomized trials in healthy...
Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products
Novo Nordisk announced steep price cuts for its GLP‑1 diabetes and obesity drugs, aiming to broaden patient access amid intensifying pricing scrutiny. AbbVie is committing $380 million to expand API manufacturing capacity, reinforcing supply‑chain resilience. Bora Pharmaceuticals and GSK sealed a...
Thermogeneration by White Fat Could Be Used to Treat Obesity
Researchers at Cornell uncovered a previously unknown thermogenic pathway in white adipocytes, where free fatty acids induce proton leakage through the mitochondrial ADP/ATP carrier (AAC). This AAC‑mediated uncoupling mirrors brown‑fat heat production without involving UCP1. In mouse models, enhancing intracellular...
Camel Antimicrobials Could Get Us over the Hump of Antibiotic Resistance
Researchers at Sultan Qaboos University have isolated three antimicrobial peptides from dromedary camels, with CdPG-3 and CdCATH showing potent activity against methicillin‑resistant Staphylococcus aureus and multidrug‑resistant Escherichia coli. The peptides kill bacteria by disrupting their membranes while exhibiting low toxicity...
The Effectiveness of TV Advertising for Pharma
Pharma TV advertising is encountering stricter regulatory limits, especially since the Trump administration tightened rules around black‑box warnings and ad volume. While TV still reaches broad audiences, its effectiveness is waning as digital platforms enable far more precise, N‑of‑1 targeting....
Revealing the Structural Fingerprints of Disease: Q&A with Faraz Choudhury
Immuto’s CEO Faraz Choudhury explains that conventional target discovery, which focuses on gene mutations and protein abundance, overlooks disease‑specific protein conformations. The company’s platform maps surface protein conformations (SPCs) in living, patient‑derived models using high‑resolution mass spectrometry and AI‑driven analysis,...
Denifanstat Posts Positive Phase III Results for Acne Treatment
Ascletis Pharma announced that its oral fatty‑acid‑synthase inhibitor denifanstat (ASC40) achieved positive Phase III results in moderate‑to‑severe acne vulgaris. In a 480‑patient double‑blind trial, 33% of participants reached clear or almost‑clear skin versus 15% on placebo, and an open‑label safety study...
Merck’s Oncology Spin-Out: Organizational Design as Patent Cliff Strategy
Merck has created a standalone oncology business unit to confront the concentration risk posed by Keytruda, which now generates over half of its pharmaceutical sales and faces patent expiry around 2028. The restructuring treats organizational design as a strategic lever...
How a Sirtuin Protects Against Brain Diseases
Researchers in Aging Cell reveal that the nuclear sirtuin SIRT6 safeguards brain health by preserving nucleolar integrity and curbing excess protein synthesis. Loss of SIRT6 triggers nucleolar enlargement, heightened rRNA production, and uncontrolled protein translation, leading to protein aggregation and...
The IPO Buzz: Generate Biomedicines (GENB Proposed) Launches $400 Million IPO
Generate Biomedicines, Inc. (GENB) launched a $400 million IPO on Feb 23, 2026, offering 25 million shares at $15‑$17 each on NASDAQ. At the midpoint price of $16, the company would be valued at roughly $2.04 billion. The proceeds are earmarked for two Phase 3 trials...
How to Achieve Superior BCMA Response Rates without the Liability of Delayed MNTs
Recent analyses of BCMA CAR‑T therapies reveal that superior response rates can be achieved without the historically accepted trade‑off of delayed movement and neurocognitive toxicities (MNTs). Emerging data pinpoint specific construct features—particularly signaling domains and hinge designs—as the primary drivers...
Karma-Karma-Karma Chameleon
Balancing potency with oral bioavailability remains a core hurdle as drug candidates grow larger and more complex. Researchers now focus on "chameleonicity"—the ability of a molecule to toggle between polar and lipophilic conformations—to reconcile solubility and permeability. The article outlines...